公司资料
Galera Therapeutics 股价、新闻与催化剂
- 股票代码:
- GRTX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
17.60 USD (-2.22%)
收盘价
最后更新: 2026年7月10日
—
市值
股价为何变动
目前无法获取 GRTX 的收盘价变动背景。
公司概览
Oncology Biotechnology Company in Transition
Galera Therapeutics entered 2026 focused on an acquired nitric-oxide-synthase inhibitor for difficult-to-treat breast cancers while pursuing a strategic combination with Obsidian Therapeutics. The planned combination shifts the principal operating focus toward engineered tumor-infiltrating lymphocyte therapies.
Tilarginine Pan-NOS Program
Tilarginine is a pan-inhibitor of nitric oxide synthase. The program is based on evidence that nitric oxide signaling can support tumor initiation, progression, metastasis, and immune suppression in certain cancers.
Metaplastic and Triple-Negative Breast Cancer
The lead Galera development focus is metaplastic breast cancer and other refractory subsets of triple-negative breast cancer, where nitric oxide synthase can be overexpressed and treatment options are limited.
Investigator-Sponsored Combination Study
An NIH-funded Phase 1/2 investigator-sponsored trial is evaluating tilarginine with nab-paclitaxel and alpelisib in metaplastic breast cancer. A separate triple-negative breast cancer study has also been contemplated through the I-SPY 2 consortium, subject to funding and development decisions.
Divested Dismutase-Mimetic Assets
Galera sold avasopasem, rucosopasem, and its other superoxide-dismutase-mimetic assets to Biossil. This transaction removed the company's former radiotherapy-support portfolio and left tilarginine as its principal legacy development asset.
Obsidian Combination and OBX-115
The strategic combination with Obsidian centers the combined company on OBX-115, an engineered autologous tumor-infiltrating lymphocyte therapy designed to produce regulated membrane-bound IL-15. OBX-115 is in clinical development for advanced melanoma and non-small cell lung cancer.
未来催化剂
- Phase 1 data for OBX-115 in non-small cell lung cancer in the first half of 2027.
- Registration-enabling OBX-115 data in advanced melanoma by year-end 2027.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。